Incidence difference of cutaneous complications in different targeted drugs for treating malignant melanoma:a network Meta-analysis
10.3969/j.issn.1671-8348.2017.12.019
- VernacularTitle:不同靶向药物治疗恶性黑色素瘤皮肤并发症发生率差异的网状Meta分析
- Author:
Hongbin GUO
;
Hongquan CHEN
;
Xiaoou LU
- Keywords:
melanoma;
targeted drugs;
cutaneous complications;
randomized controlled trials;
Bayesian network model
- From:
Chongqing Medicine
2017;46(12):1642-1647
- CountryChina
- Language:Chinese
-
Abstract:
Objective To adopt the network meta analysis method to compare the incidence difference of cutaneous squamous-cell carcinoma(SCC)and rash in 5 kinds of targeted drugs regimen for treating malignant melanoma.Methods PubMed and Cochrane Library databases were retrieved by computer.The retrieval range was from their establishment to November 2015.The network meta analysis pooled the evidences of direct and indirect comparison for evaluating the pooled odds ratio(OR)and cumulative probability of cutaneous complications occurrence difference in 5 kinds of targeted drugs regimen for treating malignant melanoma.Results Six randomized controlled trials(RCTs)conforming to the inclusion criteria were included.The meta analysis results revealed that compared with Dabrafenib+Trametinib,the cutaneous SCC occurrence rate of Vemurafenib was higher(OR=9.20,95％CI=1.26-52.53),while the rash occurrence rate of Vemurafenib+Cobimetinib was higher(OR=6.81,95％CI=1.01-41.87).The surface under the cumulative ranking curves(SUCRA)value showed that adopting Trametinib had the lowest occurrence rate for SCC,and adopting Dabrafenib+Trametinib had the lowest occurrence rate of rash.Conclusion Dabrafenib+Trametinibis generate the lowest complication incidence rate of malignant melanoma.
